Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of IL-22BP/LNP Compound in Refractory Malignant Solid Tumors

NCT07100210 is registered in ClinicalTrials.gov with Xingchen Peng as lead sponsor.

NCT NCT07100210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07100210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of IL-22BP/LNP Compound in Refractory Malignant Solid Tumors
Lead sponsor
Xingchen Peng
Phase
Phase 1
Overall status
Recruiting
Start date
January 20, 2025
Completion date
February 20, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interleukin, mrna vaccine, refractory malignant solid tumors